Phase II, multicenter, randomized study of cetuximab plus/less weekly paclitaxel after progression to first-line pembrolizumab plus platinum-5FU in subjects with recurrent/metastatic squamous cell carcinoma of the head and neck (ERBIOTAX)
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: SPANISH GROUP FOR THE TREATMENT OF HEAD AND NECK TUMORS
- Phase: II
- Execution start: 05/11/2025
- End of execution: 30/07/2028
- PI: JOAQUINA MARTINEZ GALAN
